Quantcast
Connect with us

‘Pharma Bro’ Martin Shkreli regrets nothing: AIDS drug was ‘woefully underpriced’ before

Published

on

In an interview with the Financial Times, former Turing Pharmaceuticals CEO and global poster child for prescription drug price-gauging Martin Shkreli said that he regrets nothing about his decision to raise the per-pill cost of the drug Daraprim from $13.50 to $750.

The Guardian reported Friday that Shkreli maintains that Daraprim — which is used to treat the blood disease toxoplasmosis in AIDS and cancer patients — was “woefully underpriced” before his firm jacked up the cost.

ADVERTISEMENT

“To me the drug was woefully underpriced,” he said. “It is not a question of ‘Is this fair?’ or ‘What did you pay for it?’ or ‘When was it invented?’ It should be more expensive in many ways.”

The 32-year-old hedge funder and entrepreneur then tried to style himself as a martyr to the whims of his companies’ shareholders.

“My whole life has been one theme, of self-sacrifice for my investors,” he said. “I did it for my shareholders’ benefit because that’s my job. The political risk is being shamed, and shame isn’t dilutive to earnings per share.”

Earlier this year, he told VICE that his business practices may be unpopular, but they are not unethical.

“Yea, I’m a capitalist, I’d love to make an even bigger fortune then I’ve got now,” he said. “But I’m not gonna do it at the expense of a human life. We sell our drugs for a dollar to the government, but we sell our drugs for $750 a pill to Walmart, to Exxon Mobil, to all these big companies, they pay full price because fuck them, why shouldn’t they? If I take their money to do research for dying kids, I think I’m a hero, let alone evil.”

ADVERTISEMENT

Shkreli was taken into custody by the FBI on charges of defrauding investors. He posted the $5 million bail and is awaiting trial in June.


Report typos and corrections to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

2020 Election

‘This is bad news for Trump’: Morning Joe drops bombshell on president over blowback from impeachment trial

Published

on

Referring to a new poll that shows Donald Trump is losing to virtually every Democrat who is running for their party's presidential nomination, the panel on MSNBC's "Morning Joe" suggested the president may survive impeachment but not the 2020 election.

"Why don't we see what the American people are thinking about these proceeding, because when you listen to Republicans, they will tell you that this has just been -- that Nancy Pelosi mishandled this, Adam Schiff mishandled it," host Scarborough began. "That the American people are angry and this is going to help Donald Trump and help the Republicans so much. Poll after poll after poll shows that to be a lie."

Continue Reading

Breaking Banner

Is Trump’s base of support a cult? Ask 3 people who left it

Published

on

Critics of President Donald Trump have often accused his supporters — both in government and in the public — of essentially belonging to a cult. Their senses of identity, in many cases, have become wrapped around the president, and their primary political motivations revolve around serving his whims and interests rather than any higher policy goals.

But is the “cult” label really fair? Does it accurately describe the phenomenon we’re seeing?

In a recent article for The Conversation, Sharday Mosurinjohn, a professor of cultural and religious studies at Queen’s University, argued that calling Trump’s base of support a “cult” is unhelpful.

Continue Reading
 

Breaking Banner

Republican Kevin McCarthy gets taken down by former top GOP colleague

Published

on

Rep. Kevin McCarthy (R-CA) was attacked by a former Republican colleague who alleged McCarthy and his fellow members of Congress have allowed the House GOP to become the official shill for the White House.

In a profile for the New York Times, former Oversight Committee Chairman Tom Davis (R-VA) shamed the GOP House for the way that a once-respectable institution has fallen.

“Congress no longer operates as an independent branch of government, but as an appendage of the executive branch,” said Davis. “He is made for that role.”

Continue Reading
 
 
Help Raw Story Uncover Injustice. Join Raw Story Investigates for $1 and go ad-free.
close-image